|
|
| Line 23: |
Line 23: |
| <span style="display:none">availableVariable::cancer prevalence</span> | | <span style="display:none">availableVariable::cancer prevalence</span> |
| <span style="display:none">availableVariable::screening</span> | | <span style="display:none">availableVariable::screening</span> |
| | <span style="display:none">isPracticeGuideline</span> |
| <span style="display:none">hasCancerType::C50: Breast cancer</span> | | <span style="display:none">hasCancerType::C50: Breast cancer</span> |
| <span style="display:none">isPracticeGuideline</span>
| |
| <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> | | <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> |
| <span style="display:none">hasCancerType::C00-C97: All cancer types</span> | | <span style="display:none">hasCancerType::C00-C97: All cancer types</span> |
| <span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
| |
| <span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
| |
| <span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
| |
| <span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
| |
| <span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
| |
| <span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
| |
| <span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
| |
| <span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
| |
| <span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
| |
| <span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
| |
| <span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
| |
| <span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
| |
| <span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
| |
| <span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
| |
| <span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
| |
| <span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
| |
| <span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
| |
| <span style="display:none">hasCancerType::unknown</span>
| |
Revision as of 19:07, 10 December 2025
forproviders forpolicymakers
spaincountry
Go back to Spain page
Primary purpose: To improve the clinical management of women with metastatic breast cancer in Spain by providing systematically developed recommendations for healthcare professionals, patients, and their families.
Sponsor, manager or home institution: GEICAM.
Type of information: medical procedures; cancer incidence; cancer prevalence; screening. Clinical questions to be addressed, methodology, diagnosis, various treatment options for metastatic breast cancer, management of specific metastatic locations, other relevant clinical situations, and follow-up and response evaluation.
Cancer Areas of Interest: C50: Breast cancer.
Access to information: Click here to access.
Lobular
Breast
Nipple
Areola
Ductal
dataOwner::GEICAM
availableVariable::medical procedures
availableVariable::cancer incidence
availableVariable::cancer prevalence
availableVariable::screening
isPracticeGuideline
hasCancerType::C50: Breast cancer
hasCancerType::C00-D48: All neoplasms
hasCancerType::C00-C97: All cancer types
